AU2004204462B2 - Dual expression vector system for antibody expression in bacterial and mammalian cells - Google Patents

Dual expression vector system for antibody expression in bacterial and mammalian cells Download PDF

Info

Publication number
AU2004204462B2
AU2004204462B2 AU2004204462A AU2004204462A AU2004204462B2 AU 2004204462 B2 AU2004204462 B2 AU 2004204462B2 AU 2004204462 A AU2004204462 A AU 2004204462A AU 2004204462 A AU2004204462 A AU 2004204462A AU 2004204462 B2 AU2004204462 B2 AU 2004204462B2
Authority
AU
Australia
Prior art keywords
vector
cell
bacterial
mammalian
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
AU2004204462A
Other languages
English (en)
Other versions
AU2004204462A1 (en
Inventor
Ling Huang
Leslie Sydnor Johnson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Macrogenics Inc
Original Assignee
Macrogenics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macrogenics Inc filed Critical Macrogenics Inc
Publication of AU2004204462A1 publication Critical patent/AU2004204462A1/en
Application granted granted Critical
Publication of AU2004204462B2 publication Critical patent/AU2004204462B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/14011—Details ssDNA Bacteriophages
    • C12N2795/14041—Use of virus, viral particle or viral elements as a vector
    • C12N2795/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2004204462A 2003-01-09 2004-01-08 Dual expression vector system for antibody expression in bacterial and mammalian cells Expired - Fee Related AU2004204462B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43949203P 2003-01-09 2003-01-09
US60/439,492 2003-01-09
PCT/US2004/000462 WO2004063343A2 (en) 2003-01-09 2004-01-08 Dual expression vector system for antibody expression in bacterial and mammalian cells

Publications (2)

Publication Number Publication Date
AU2004204462A1 AU2004204462A1 (en) 2004-07-29
AU2004204462B2 true AU2004204462B2 (en) 2012-03-08

Family

ID=32713489

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004204462A Expired - Fee Related AU2004204462B2 (en) 2003-01-09 2004-01-08 Dual expression vector system for antibody expression in bacterial and mammalian cells

Country Status (8)

Country Link
US (3) US7112439B2 (https=)
EP (1) EP1588166A4 (https=)
JP (1) JP4773947B2 (https=)
AU (1) AU2004204462B2 (https=)
BR (1) BRPI0406662A (https=)
CA (1) CA2513025A1 (https=)
IL (1) IL169604A (https=)
WO (1) WO2004063343A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11795579B2 (en) 2017-12-11 2023-10-24 Abalone Bio, Inc. Yeast display of proteins in the periplasmic space

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006512891A (ja) * 2002-04-18 2006-04-20 ジェネンコー・インターナショナル・インク 糸状菌における機能性抗体の生産
US20040067532A1 (en) 2002-08-12 2004-04-08 Genetastix Corporation High throughput generation and affinity maturation of humanized antibody
EP1588166A4 (en) * 2003-01-09 2007-06-27 Macrogenics Inc VECTOR SYSTEM WITH DOUBLE EXPRESSION FOR EXPRESSING ANTIBODIES IN BACTERIAL AND MAMMAL CELLS
JP2007521832A (ja) * 2004-09-07 2007-08-09 クロネックス・ディベロップメント・インコーポレイテッド 細胞培養からのタンパク質収量の増加において使用するための細胞株
CA2589937C (en) * 2004-12-07 2014-04-22 Lonza Ag Rhamnose promoter expression system
EP1915394B1 (en) 2005-05-20 2021-01-27 Lonza Biologics plc. High-level expression of recombinant antibody in a mammalian host cell
WO2008024998A2 (en) * 2006-08-24 2008-02-28 Virovek, Inc. Expression in insect cells of genes with overlapping open reading frames, methods and compositions therefor
AU2007352346B2 (en) * 2006-10-30 2012-12-06 Eli Lilly And Company Random homozygous gene perturbation to enhance antibody production
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
EP3124497B1 (en) 2007-09-14 2020-04-15 Adimab, LLC Rationally designed, synthetic antibody libraries and uses therefor
US12529164B2 (en) 2007-09-14 2026-01-20 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US20110033476A1 (en) * 2007-11-12 2011-02-10 Theraclone Sciences Inc. Compositions and methods for the therapy and diagnosis of influenza
JP4932940B2 (ja) 2007-11-12 2012-05-16 セラクローン サイエンシーズ， インコーポレイテッド インフルエンザの治療および診断のための組成物および方法
US20090162845A1 (en) * 2007-12-20 2009-06-25 Elazar Rabbani Affinity tag nucleic acid and protein compositions, and processes for using same
WO2009123894A2 (en) 2008-04-02 2009-10-08 Macrogenics, Inc. Her2/neu-specific antibodies and methods of using same
ES2589912T3 (es) 2008-04-02 2016-11-17 Macrogenics, Inc. Anticuerpos específicos para el complejo BCR y procedimientos de uso de los mismos
US20110081347A1 (en) 2008-06-04 2011-04-07 Macrogenics, Inc. Antibodies with Altered Binding to FcRn and Methods of Using Same
EP2344686B1 (en) 2008-10-03 2014-03-05 XOMA Technology Ltd. Novel triple tag sequences and methods of use thereof
WO2010096394A2 (en) 2009-02-17 2010-08-26 Redwood Biosciences, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
SI3260136T1 (sl) 2009-03-17 2021-05-31 Theraclone Sciences, Inc. Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
US8609101B2 (en) * 2009-04-23 2013-12-17 Theraclone Sciences, Inc. Granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralizing antibodies
EP2432803A2 (en) 2009-05-20 2012-03-28 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
EP2445539A4 (en) * 2009-06-26 2015-05-20 Five Prime Therapeutics Inc VALIDATION OF TARGETS OF THERAPEUTIC ANTIBODIES AND IN VIVO SCREENING
CA2807664A1 (en) 2010-08-12 2012-02-16 Theraclone Sciences, Inc. Anti-hemagglutinin antibody compositions and methods of use thereof
PT3556396T (pt) 2010-08-31 2022-07-04 Scripps Research Inst Anticorpos neutralizantes do vírus da imunodeficiência humana (vih)
WO2012097333A2 (en) 2011-01-14 2012-07-19 Redwood Bioscience, Inc. Aldehyde-tagged immunoglobulin polypeptides and method of use thereof
WO2012112489A2 (en) 2011-02-14 2012-08-23 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
BR112013023576A2 (pt) 2011-03-15 2016-12-06 Theraclone Sciences Inc composições e métodos para a terapia e diagnóstico de influenza
US8822651B2 (en) 2011-08-30 2014-09-02 Theraclone Sciences, Inc. Human rhinovirus (HRV) antibodies
ES3011307T3 (en) 2012-02-23 2025-04-07 Juno Therapeutics Gmbh Chromatographic isolation of cells and other complex biological materials
US9803191B2 (en) * 2012-07-05 2017-10-31 Genentech, Inc. Expression and secretion system
WO2014100073A2 (en) * 2012-12-21 2014-06-26 Merck Sharp & Dohme Corp. Expression vectors for recombinant protein production in mammalian cells
SG11201605203UA (en) 2013-12-24 2016-07-28 Argen X N V Fcrn antagonists and methods of use
ES2763526T3 (es) * 2014-07-03 2020-05-29 Hoffmann La Roche Sistemas de expresión de polipéptidos
TWI870335B (zh) 2015-06-12 2025-01-21 美商宏觀基因股份有限公司 變異的嵌合4d5抗體及其與抗pd-1抗體聯合用於治療癌症的應用
EP3786293A1 (en) 2015-06-12 2021-03-03 AxioMx, Inc. Methods and compositions for producing a chimeric polypeptide
EP3365453A2 (en) 2015-10-22 2018-08-29 Juno Therapeutics GmbH Methods, kits, agents and apparatuses for transduction
MX2018004875A (es) 2015-10-22 2018-08-01 Juno Therapeutics Gmbh Metodos para cultivar celulas y kits y aparatos para ello.
JP2019515677A (ja) 2016-04-26 2019-06-13 アール．ピー．シェーラー テクノロジーズ エルエルシー 抗体複合体ならびにそれを作製および使用する方法
GB201617270D0 (en) 2016-10-11 2016-11-23 Argen-X N V And Fairjourney Biologics Triple vector for expressing antibody molecules in full therapeutic format
JP7339160B2 (ja) 2017-04-27 2023-09-05 ジュノ セラピューティクス ゲーエムベーハー オリゴマー粒子試薬およびその使用方法
CA3081144A1 (en) 2017-12-08 2019-06-13 Argenx Bvba Use of fcrn antagonists for treatment of generalized myasthenia gravis
US12202900B2 (en) 2018-06-08 2025-01-21 argenx BV Compositions and methods for treating immune thrombocytopenia
SG11202104355SA (en) 2018-10-31 2021-05-28 Juno Therapeutics Gmbh Methods for selection and stimulation of cells and apparatus for same
JP7565951B2 (ja) 2019-06-07 2024-10-11 アルジェニクス ビーブイ 皮下投与に好適なＦｃＲｎインヒビターの医薬製剤
CN114423787B (zh) 2019-07-19 2025-01-24 昂科里斯庞斯公司 免疫调节性抗体及其使用方法
JP2023509195A (ja) 2020-01-08 2023-03-07 アルジェニクス ビーブイ 天疱瘡症を治療する方法
BR112023014418A2 (pt) 2021-01-20 2023-10-31 Oncoresponse Inc Anticorpos imunomoduladores e usos dos mesmos
CN119698429A (zh) 2022-06-15 2025-03-25 阿根思有限公司 Fcrn结合分子及使用方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
US5807715A (en) * 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
DE4237113B4 (de) 1992-11-03 2006-10-12 "Iba Gmbh" Peptide und deren Fusionsproteine, Expressionsvektor und Verfahren zur Herstellung eines Fusionsproteins
US6627436B2 (en) * 1997-10-31 2003-09-30 Stratagene Vector for gene expression in prokaryotic and eukaryotic systems
IL143027A0 (en) * 1998-11-16 2002-04-21 Genway Biotech Inc Generation of antibodies using polynucleotide vaccination in avian species
US7244592B2 (en) * 2002-03-07 2007-07-17 Dyax Corp. Ligand screening and discovery
EP1588166A4 (en) 2003-01-09 2007-06-27 Macrogenics Inc VECTOR SYSTEM WITH DOUBLE EXPRESSION FOR EXPRESSING ANTIBODIES IN BACTERIAL AND MAMMAL CELLS

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11795579B2 (en) 2017-12-11 2023-10-24 Abalone Bio, Inc. Yeast display of proteins in the periplasmic space

Also Published As

Publication number Publication date
CA2513025A1 (en) 2004-07-29
EP1588166A4 (en) 2007-06-27
IL169604A0 (en) 2007-07-04
JP2006516195A (ja) 2006-06-29
US20070037216A1 (en) 2007-02-15
US7112439B2 (en) 2006-09-26
US7906327B2 (en) 2011-03-15
JP4773947B2 (ja) 2011-09-14
WO2004063343A3 (en) 2005-06-30
IL169604A (en) 2011-04-28
US20040197866A1 (en) 2004-10-07
AU2004204462A1 (en) 2004-07-29
WO2004063343A2 (en) 2004-07-29
BRPI0406662A (pt) 2005-12-20
US20110136689A1 (en) 2011-06-09
EP1588166A2 (en) 2005-10-26

Similar Documents

Publication Publication Date Title
AU2004204462B2 (en) Dual expression vector system for antibody expression in bacterial and mammalian cells
JP6945444B2 (ja) 高親和性ｐｄ−１薬剤とその使用方法
US10492476B2 (en) Non-human mammals for the production of chimeric antibodies
JP6875385B2 (ja) 抗ｐｄ−１抗体および組成物
US7435549B1 (en) Method of identifying binding site domains that retain the capacity of binding to an epitope
US20240299507A1 (en) Humanized anti-muc1* antibodies and direct use of cleavage enzyme
CN110177876A (zh) 抗gpc3抗体
KR20080113236A (ko) Ｒａｇｅ를 길항하기 위한 방법 및 조성물
ES2872048T3 (es) Métodos celulares para acoplar interacciones de proteínas y selección y diversificación de moléculas de unión
JP2019524094A (ja) Ｔｇｆｂ抗体、方法、及び使用
JP2019512230A (ja) Ｇｉｔｒ抗体、方法、及び使用
KR102139388B1 (ko) 친화성 성숙 인간 항체의 동정
KR20230150779A (ko) 중쇄-단독 항체
US20190292275A1 (en) Sequencing-directed selection of tumor theranostics
JP6442411B2 (ja) 新規な細胞株スクリーニング方法
JP7085992B2 (ja) 共通軽鎖を有するトランスジェニックウサギ
JP2020533953A (ja) ＭＡｄＣＡＭに対する抗体
WO2025082254A1 (zh) 一种抗人hhla2的纳米抗体及其应用
Huhtinen ADVANCING ANTIBODY ENGINEERING
McLaren The generation of recombinant phage antibodies to the multiple drug resistance protein p-glycoprotein

Legal Events

Date Code Title Description
MK25 Application lapsed reg. 22.2i(2) - failure to pay acceptance fee